Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoSec Medical Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
OncoSec Medical Enters into Research Agreement with University of California 12
OncoSec Medical Enters into Agreement with Merck 13
Avacta Enters into Research Agreement with OncoSec Medical 14
OncoSec Medical Enters into Agreement with Jounce Therapeutics 15
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 16
OncoSec Medical Enters into Research Agreement with University of Washington 17
Licensing Agreements 18
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 18
Equity Offering 19
OncoSec Medical Raises USD8 Million in First Tranche of Private Placement of Shares 19
OncoSec Medical Raises USD23 Million in Public Offering of Shares 20
OncoSec Medical Plans to Raise up to USD16 Million in Public Offering of Shares 21
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoSec Medical Raises USD7 Million in Private Placement of Shares 23
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 25
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 26
OncoSec Medical Raises USD10 Million in Registered Direct Offering 27
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 28
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 29
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 30
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 31
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 32
OncoSec Medical Completes Public Offering Of Units For US$8 Million 33
OncoSec Medical Inc – Key Competitors 35
OncoSec Medical Inc – Key Employees 36
OncoSec Medical Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 25, 2017: OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017 38
Jun 01, 2017: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017 40
Mar 16, 2017: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017 42
Corporate Communications 43
Jul 16, 2018: OncoSec names Sara M. Bonstein as chief financial officer and chief operating officer 43
Jun 25, 2018: OncoSec added to the Russell Microcap Index 44
Jan 16, 2018: OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors 45
Dec 05, 2017: OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to CSO 46
Nov 07, 2017: OncoSec Appoints Daniel J. O’Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company 47
Sep 07, 2017: OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors 48
Sep 05, 2017: OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors 49
Product Approvals 50
Jun 08, 2017: OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma 50
Feb 27, 2017: OncoSec Granted FDA Fast Track Designation for ImmunoPulse IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab 51
Clinical Trials 52
Apr 03, 2017: OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting 52
Mar 21, 2017: OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models 53
Feb 23, 2017: OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients 54
Feb 08, 2017: OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February 55
Other Significant Developments 56
Jun 28, 2018: OncoSec provides outlook for second half of 2018 56
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoSec Medical Inc, Deals By Therapy Area, 2012 to YTD 2018 9
OncoSec Medical Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoSec Medical Enters into Research Agreement with University of California 12
OncoSec Medical Enters into Agreement with Merck 13
Avacta Enters into Research Agreement with OncoSec Medical 14
OncoSec Medical Enters into Agreement with Jounce Therapeutics 15
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 16
OncoSec Medical Enters into Research Agreement with University of Washington 17
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 18
OncoSec Medical Raises USD8 Million in First Tranche of Private Placement of Shares 19
OncoSec Medical Raises USD23 Million in Public Offering of Shares 20
OncoSec Medical Plans to Raise up to USD16 Million in Public Offering of Shares 21
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoSec Medical Raises USD7 Million in Private Placement of Shares 23
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 25
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 26
OncoSec Medical Raises USD10 Million in Registered Direct Offering 27
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 28
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 29
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 30
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 31
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 32
OncoSec Medical Completes Public Offering Of Units For US$8 Million 33
OncoSec Medical Inc, Key Competitors 35
OncoSec Medical Inc, Key Employees 36
OncoSec Medical Inc, Other Locations 37
List of Figures
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoSec Medical Inc, Medical Devices Deals, 2012 to YTD 2018 10
